Life Sciences Outlook 2012 Dutch biotech companies ... - NautaDutilh

More documents

Recommendations

Info

Luxembourg Luxembourg Margaretha Wilkenhuysen Vincent Wellens Partner Luxembourg T: +352 26 12 29 32 M: +352 691 12 29 32 E: greet.wilkenhuysen@nautadutilh.com Luxembourg T: +352 26 12 29 34 M: +352 621 15 61 78 E: vincent.wellens@nautadutilh.com Margaretha Wilkenhuysen is a partner in our Luxembourg corporate practice. She specializes in cross-border corporate transactions, with a particular focus on mergers and acquisitions, joint ventures and international corporate restructurings. Margaretha also has extensive experience in corporate finance. Her clients include major international corporations and she has represented both domestic and international clients in a variety of high-end transactions. Margaretha has been involved in transactions for several life sciences clients, such as Johnson & Johnson and Pfizer. Vincent Wellens heads our Luxembourg IP/ICT & competition practice. His recent work for life sciences clients includes representing a major US life sciences player in an ICDR arbitration on the spin-off of a Belgian university and representing a major pharmaceutical group before the Luxembourg regulatory authority with respect to the marketing authorisation for the generic version of one of its products. He also lectures on R&D contracts at the Luxembourg School of Commerce. 50
Disclaimer. This publication contains general information on current and upcoming legal and market issues and trends. It is not intended to be comprehensive or to provide legal, tax or commercial advice. Copyright: NautaDutilh N.V. Date: 9 May 2012 Author: Jeroen Kerkhof Support: Pier Beerda Life Sciences Outlook 2012 Dutch biotech companies: from start-up to exit 51
Page 1: Life Sciences Outlook 2012 Dutch bi
Page 5 and 6: Table of contents. Preface 3 Introd
Page 7: will flow through the Netherlands O
Page 10 and 11: Academic institutes as the Petri di
Page 12 and 13: “You don’t start a biotech comp
Page 14 and 15: Best practice in life sciences tech
Page 16 and 17: The role of government “One thing
Page 19 and 20: 2. Investing. At the point that a s
Page 21 and 22: “We also have ourselves to blame,
Page 23 and 24: “Life sciences are far more diffi
Page 25: The evolving relationship between m
Page 28 and 29: A lack of ambition or healthy reali
Page 30 and 31: The term ‘strategic alliance’ i
Page 33 and 34: 4. Exit strategy. The last stage in
Page 35 and 36: In each case, a decision will have
Page 37 and 38: “IPOs are currently financing eve
Page 39 and 40: The technical IPO or even a hybrid
Page 41 and 42: However, the government could becom
Page 43 and 44: Galapagos NV: Onno van de Stolpe (C
Page 45 and 46: About Niaba. The Netherlands Biotec
Page 47 and 48: The Netherlands The Netherlands Joh
Page 49: The Netherlands Belgium Bart van Ke
Page 53: Life Sciences Outlook 2012 Dutch bi

Life Sciences Outlook 2012 Dutch biotech companies ... - NautaDutilh

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?